Given the heterogeneity of sepsis patients, many clinical trials targeting the hyper-inflammatory response in sepsis, including corticosteroids, and anti-cytokine therapies (e.g., anti-IL1 and anti TNF-α) have yielded disappointing results (21, 22). The gene discussed is IL1B; the disease is Sepsis.